Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.89 Average Target Price from Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $58.89.

Several analysts have recently issued reports on the company. Oppenheimer upped their price objective on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, June 2nd. Wall Street Zen upgraded Immunocore from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. Finally, Needham & Company LLC restated a "buy" rating and issued a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th.

Immunocore Price Performance

IMCR stock traded up $0.26 during midday trading on Friday, hitting $31.38. 296,110 shares of the stock were exchanged, compared to its average volume of 348,420. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.31 and a current ratio of 6.36. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -72.98 and a beta of 0.83. Immunocore has a fifty-two week low of $23.15 and a fifty-two week high of $41.54. The stock's 50-day moving average price is $32.06 and its 200-day moving average price is $30.28.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 6.48% and a negative return on equity of 5.86%. The company had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same quarter in the previous year, the business posted ($0.49) earnings per share. The firm's quarterly revenue was up 33.6% compared to the same quarter last year. Research analysts predict that Immunocore will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunocore

A number of large investors have recently added to or reduced their stakes in IMCR. Baker BROS. Advisors LP increased its position in shares of Immunocore by 53.3% during the first quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company's stock worth $68,913,000 after acquiring an additional 807,338 shares during the last quarter. Groupama Asset Managment purchased a new position in shares of Immunocore during the 4th quarter valued at approximately $17,700,000. Deep Track Capital LP bought a new stake in shares of Immunocore in the fourth quarter worth $15,322,000. Tang Capital Management LLC raised its holdings in Immunocore by 40.7% in the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after acquiring an additional 450,000 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Immunocore during the 4th quarter worth $11,897,000. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.